EZETIMIBE AND SIMVASTATIN (ezetimibe; simvastatin) by ANI Pharmaceuticals is synthesis. Approved for total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction, stroke and 5 more indications. First approved in 2025.
Drug data last refreshed 20h ago
synthesis. Ezetimibe and simvastatin tablets contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe…
Worked on EZETIMIBE AND SIMVASTATIN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study
LDL Receptor Under Ezetimibe and Simvastatin